CClinicalTrials.gg
Status unknownNCT00743977Updated Aug 29, 2008

Bioequivalence of Phenazopyridine HCl in Healthy Volunteers

An interventional study of Phenazopyridine HCl in Human Volunteers, sponsored by Universal Enterprises. Status unknown at 1 site in Pakistan. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-08-29.

Sponsored by Universal Enterprises · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Aug 2008), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The present study aims at comparing the pharmacokinetics of the original formulation of phenazopyridine and a same generic product.

02

Conditions studied

  • Human Volunteers
03

In context

Lead sponsor

This is the only study on the registry with Universal Enterprises as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy subjects aged 18 to 55 (Male \& Female)
  • Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests
  • Informed consent signed by the subject
  • The subject is co-operative and available for the entire study
  • Not pregnant or nursing
  • Normal renal and hepatic function

Exclusion criteria

Exclusion Criteria:

  • Evidence in the subject medical history or in the medical examination of any clinically significant hepatic, renal, gastrointestinal, cardiovascular, pulmonary, hematological or other significant acute or chronic abnormalities which might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the active agent under investigation
  • Hypersensitivity to subject drug, atopic eczema or allergic bronchial asthma
  • Evidence of hypertension (blood pressure after 3 minutes sitting>160/95 mm Hg)
  • Evidence of chronic or acute infectious diseases;
  • History or evidence of malignant tumors;
  • Evidence of hyperuricaemia, elevated serum uric acid (>8.0 mg/dl)
  • Hepatic or renal impairment; elevated serum creatinine (>1.4 mg/dl)
  • Planned vaccination during the time course of the study
  • Adherence to a diet (i.e, vegetarian) or life style (incl. extreme sports) that might interfere with the investigation
  • Laboratory test results outside the tolerance values as laid down by the study centre, which may be an evidence of disease. Positive result of HIV1/2, HCV antibody or HBs antigen testing
  • Regular use of any medication within four weeks prior to commencement of the study (self-medication or prescription)
  • Single use of any medication (including OTC) that are not expressively permitted within two weeks prior to start of the study
  • Abuse of alcohol, caffeine or tobacco (equivalent to more than 10 cigarettes a day)
  • Drug addiction
  • Participation in a clinical investigation or blood donation of more than 250 ml within the past eight weeks or blood donation of less than 250 ml within the past 4 week
  • Subjects who are known or suspected

    • not to comply with the study directives
    • not to be reliable or trustworthy
    • not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent),in particular regarding the risks and discomfort to which they would agree to be exposed.
    • to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    A

    Drug: Phenazopyridine HCl

  • Experimental
    B

    Drug: Phenazopyridine HCl

Interventions

  • DrugPhenazopyridine HCl

    100mg tablet in fasting state

    Also known as: Pyridium

06

What researchers measure

Primary outcomes

  1. The primary outcome of the study will be to determine the bioequivalence of both the formulations of phenazopyridine

    Time frame: regular intervals after drug dosing

07

Study locations

1 site
  • Health Care Hospital
    Karachi, Pakistan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00743977
Lead sponsor
Universal Enterprises
First posted
Aug 29, 2008
Start date
Aug 2008
Primary completion
Nov 2008 (estimated)
Last update
Aug 29, 2008

Study contacts

Waqar H. Kazmi, M.D, M.S.
principal investigator

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion